<p>ELISA depicts the seroreactivity of twice and thrice intranasally or intramuscularly vaccinated mice (cohort II: cH6/1, cH5/1, +/- cH9/1) to a variety of subtype H1 influenza viruses including (A) A/Puerto Rico/8/34 which has a stalk domain homologous to the cHA immunogens. Seroreactivity to heterologous H1N1 subtype strains including (B) pH1N1 (A/Netherlands/602/2009) and two drifted seasonal isolates, (C) A/USSR/90/1977 and (D) A/Brisbane/59/2007, is also demonstrated by ELISA. Error bars represent the standard deviation for replicates of pooled serum samples. Animals receiving two administrations of poly(I:C) alone (Adjuvant Only) IN were not bled at this timepoint so no data (nd) were generated.</p
Here we define the epitopes on HA that are targeted by a group of 9 recombinant monoclonal antibodie...
<p>Serum samples from the mice described in the legend to Fig. 1 were collected on day 20 and day 34...
Exposure to contemporary seasonal influenza A viruses affords partial immunity to pandemic H1N1 2009...
<p>Mice sequentially immunized (cohort III: cH9/1, cH6/1 and H1 soluble protein) are seroreactive to...
<p>Culture supernatants of various hybrid cell clones generated against pandemic H1N1 virus were tes...
<p>A) Timeline for immunization and challenge. B) Influenza H5N1 virus specific serum IgG antibody t...
<p>ELISA was used to determine the HA stalk-specific seroreactivity induced by the vaccination strat...
<p>BALB/c mice (n = 10) were vaccinated with f88M2e2-16, f88-ctr, human M2eHBc or PBS three times in...
<p>Induction of influenza H1N1-specific immune responses after subcutaneous immunization of Balb/c m...
<p>HI titer (A) and antigen-specific antibodies (IgG—B, IgG1 – C and IgG2a—D) responses at week 4 in...
Influenza A virus subtypes are classified on the basis of the antigenicity of their envelope glycopr...
<p>Control mice or mice primed with a non-lethal dose of Philippines/2/82/X-79, were subsequently va...
<p>ELISA showing binding of 18 purified single domain VHH antibodies to influenza reference reagents...
(A) Serial dilutions of HA tri-stalk protein (0.15625, 0.3125, 0.625, 1.25, 2.5, 5.0 and 10.0 μg/mL)...
<p>Sera from 10 days post-last vaccination were used for the detection. (A) Detection of sera IgG an...
Here we define the epitopes on HA that are targeted by a group of 9 recombinant monoclonal antibodie...
<p>Serum samples from the mice described in the legend to Fig. 1 were collected on day 20 and day 34...
Exposure to contemporary seasonal influenza A viruses affords partial immunity to pandemic H1N1 2009...
<p>Mice sequentially immunized (cohort III: cH9/1, cH6/1 and H1 soluble protein) are seroreactive to...
<p>Culture supernatants of various hybrid cell clones generated against pandemic H1N1 virus were tes...
<p>A) Timeline for immunization and challenge. B) Influenza H5N1 virus specific serum IgG antibody t...
<p>ELISA was used to determine the HA stalk-specific seroreactivity induced by the vaccination strat...
<p>BALB/c mice (n = 10) were vaccinated with f88M2e2-16, f88-ctr, human M2eHBc or PBS three times in...
<p>Induction of influenza H1N1-specific immune responses after subcutaneous immunization of Balb/c m...
<p>HI titer (A) and antigen-specific antibodies (IgG—B, IgG1 – C and IgG2a—D) responses at week 4 in...
Influenza A virus subtypes are classified on the basis of the antigenicity of their envelope glycopr...
<p>Control mice or mice primed with a non-lethal dose of Philippines/2/82/X-79, were subsequently va...
<p>ELISA showing binding of 18 purified single domain VHH antibodies to influenza reference reagents...
(A) Serial dilutions of HA tri-stalk protein (0.15625, 0.3125, 0.625, 1.25, 2.5, 5.0 and 10.0 μg/mL)...
<p>Sera from 10 days post-last vaccination were used for the detection. (A) Detection of sera IgG an...
Here we define the epitopes on HA that are targeted by a group of 9 recombinant monoclonal antibodie...
<p>Serum samples from the mice described in the legend to Fig. 1 were collected on day 20 and day 34...
Exposure to contemporary seasonal influenza A viruses affords partial immunity to pandemic H1N1 2009...